L 756423
Alternative Names: L-756423Latest Information Update: 09 May 2022
At a glance
- Originator Merck & Co
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 31 Aug 2021 Merck Sharp & Dohme initiates a phase II trial for HIV Infections in USA (NCT00002452)
- 24 Jun 2005 Merck Sharp & Dohme completes a phase II trial for HIV Infections in USA (NCT00002452)
- 18 Nov 1999 Phase-II clinical trials for HIV infections treatment in USA (PO)